Atorvastatin

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cardiovascular Disease

Conditions

Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease

Trial Timeline

Apr 1, 1998 → Aug 1, 2004

NCT ID

NCT00327691

About Atorvastatin

Atorvastatin is a approved stage product being developed by Pfizer for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00327691. Target conditions include Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01186289	Pre-clinical	Withdrawn	Oct 1, 2010	Oct 1, 2012	Neurocognitive Dysfunction
NCT00993915	Pre-clinical	Completed	Apr 1, 2010	Dec 1, 2011	Cardiovascular Diseases
NCT00827606	Phase 3	Completed	Mar 1, 2009	Oct 1, 2013	Familial Hypercholesterolemia
NCT00772564	Approved	Completed	Aug 1, 2008	Aug 1, 2010	Myocardial Infarction
NCT00917644	Approved	Completed	Jul 1, 2008	Sep 1, 2008	Hypercholesterolemia
NCT00540293	Approved	Completed	Oct 1, 2007	May 1, 2008	Dyslipidemias
NCT00576576	Pre-clinical	Completed	Jul 1, 2007	Mar 1, 2010	Atherosclerosis
NCT00432354	Phase 2/3	UNKNOWN	Mar 1, 2007	Mar 1, 2009	Systemic Lupus Erythematosus
NCT00172419	Pre-clinical	Completed	Mar 1, 2007	Dec 1, 2008	Hyperlipidemia
NCT00441597	Approved	Completed	Feb 1, 2007	Mar 1, 2009	Ischemia Reperfusion Injury
NCT00343655	Phase 3	Terminated	Jan 1, 2007	Aug 1, 2007	Cardiovascular Diseases
NCT00640744	Approved	UNKNOWN	Feb 1, 2006	Feb 1, 2010	Atherosclerosis
NCT00136942	Phase 3	Completed	Apr 1, 2005	—	Hyperlipidemia
NCT01785615	Phase 1/2	Completed	Nov 1, 2004	May 1, 2013	Metabolic Syndrome
NCT00150371	Phase 3	Completed	Jun 1, 2004	May 1, 2005	Hypercholesterolemia
NCT00644709	Approved	Completed	Sep 1, 2003	Mar 1, 2005	Dyslipidemias
NCT00163150	Approved	Completed	Jun 1, 2003	Feb 1, 2006	Cerebrovascular Accident
NCT00151502	Phase 3	Completed	Nov 1, 2002	Jul 1, 2007	Alzheimer's Disease
NCT00163202	Approved	Completed	Jun 1, 2002	Aug 1, 2005	Coronary Arteriosclerosis
NCT00124397	Approved	Completed	Jul 1, 2001	Dec 1, 2004	Type 2 Diabetes Mellitus

Competing Products

20 competing products in Cardiovascular Disease

See all competitors

Product	Company	Stage	Hype Score
Dulaglutide + Placebo	Eli Lilly	Phase 3	77
raloxifene + placebo	Eli Lilly	Phase 3	77
Evacetrapib	Eli Lilly	Phase 1	33
Orforglipron + Placebo	Eli Lilly	Phase 3	77
Prasugrel (CS-747) + Clopidogrel	Eli Lilly	Phase 2	52
Rosuvamibe + Monorova	Yuhan	Approved	85
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin	Yuhan	Approved	85
Rosuvamibe + Monorova	Yuhan	Approved	85
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)	Daiichi Sankyo	Approved	85
Lexiscan	Astellas Pharma	Phase 2	52
mirabegron + tamsulosin	Astellas Pharma	Phase 1	33
TRC150094	Torrent Pharmaceuticals	Phase 1/2	41
Lorcaserin hydrochloride + Placebo	Eisai	Approved	85
Lepodisiran Sodium + Placebo	Eli Lilly	Phase 3	77
Retatrutide + Placebo	Eli Lilly	Phase 3	77
Empagliflozin + Placebos	Eli Lilly	Approved	85
Evacetrapib + Placebo	Eli Lilly	Phase 3	77
Placebo + AZD0780	AstraZeneca	Phase 2	52
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	23
Midazolam + AZD5718	AstraZeneca	Phase 1	33

Other Products from Pfizer